Fundraising Fox

Phosplatin Therapeutics

New York, US · Delaware corporation

Biotech

Founders & leadership

FB
Frances BonhamNamed on SEC filing
RF
Robert FallonNamed on SEC filing
MP
Matthew PriceNamed on SEC filing
PE
Peter EspigNamed on SEC filing
JC
John CaouetteNamed on SEC filing
RL
Rosita LeongNamed on SEC filing
JP
John PorterNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$72.3M disclosed across 3 rounds · 2018–2021

▶$37.3MraisedDec 2021 · 41 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rosita LeongDirector
  • Robert FallonExecutive Officer, Director
  • John CaouetteDirector
  • Peter EspigDirector
  • Frances BonhamExecutive Officer
  • Neil SunderlandDirector
  • Charles StuckeyDirector
  • Elizabeth TallettDirector
  • Matthew PriceDirector
Offering amount
$37.3M
Amount sold
$37.3M
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.4MraisedAug 2020 · 40 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John PorterDirector
  • Frances BonhamExecutive Officer
  • John CaouetteDirector
  • Fallon RobertExecutive Officer, Director
  • Matthew PriceExecutive Officer, Director
  • Rosita LeongDirector
  • Neil SunderlandDirector
  • Peter EspigDirector
Offering amount
$18.4M
Amount sold
$18.4M
Minimum investment
$50K
First sale
Jul 2020
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.6MraisedNov 2018 · 48 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Frances BonhamExecutive Officer
  • Robert FallonExecutive Officer, Director
  • Matthew PriceExecutive Officer, Director
  • Peter EspigDirector
  • John CaouetteDirector
  • Rosita LeongDirector
  • John PorterDirector
Offering amount
$16.6M
Amount sold
$16.6M
First sale
Oct 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Promontory Therapeutics 'can't hire fast enough' amid expansionfiercebiotech.com · Jun 2022Phosplatin Therapeutics Announces $37 Million Series A Financingprnewswire.com · Dec 2021Robert Fallon of Phosplatin Therapeutics: How Busy Leaders Create Equilibrium or Balance Between Their Work and Family Lives | by Authority Magazine Editorial Staff | Authority Magazine | Mediummedium.com · Jan 2021Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for its Novel Therapeutic Agent in Oncology, PT-112 | Promontory Therapeutics | Advancing small molecule immunotherapypromontorytx.com · Aug 2015Phosplatin Therapeutics Announces First Patients Enrolled in Phase I First-in-Human Clinical Trial in Solid Tumors | Promontory Therapeutics | Advancing small molecule immunotherapypromontorytx.com · Oct 2014

Frequently asked questions

How much funding has Phosplatin Therapeutics raised?
Phosplatin Therapeutics has disclosed $72.3M raised across 3 rounds.
Where is Phosplatin Therapeutics headquartered?
Phosplatin Therapeutics is headquartered in New York, US.